ACRS - Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon
- BiotechValley Insights is initiating coverage of ACRS with a "Bullish" rating.
- ATI-450 is a novel oral MK2 inhibitor that demonstrated comparable efficacy and superior safety over Jak inhibitors during Ph2. The oral route of administration offers a superior convenience over biological DMARDs.
- MK2 inhibitors may be scalable to numerous autoimmune diseases; the autoimmune disease market is projected to be US$65b.
- 2021 is a year where ACRS may have many potential catalysts lined up including potential big-pharma partnership/licensing-out and various data-readout for AD, CAPS, and COVID-19 trials.
For further details see:
Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon